Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Gail J. Roboz discusses the use of MRD as a target for the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). © 2019 Imedex, an HMP Company
Measurable Residual Disease (MRD) in AML and ALL
